In summary, we hypothesize that the administration of ruscogenin can attenuate DSS-induced colitis by improving intestinal barrier function, reducing the inflammation response and regulating pyroptosis via TLR4/NF-κB signaling pathway. This evidence concerns the gene NFKB1 and colitis.